Last 12 months
Inside the activity.
0 purchase rows · 33 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 3 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2021 Filed Oct 5, 2021 19:49 UTC |
Edick Paul RDirector · See Remarks
|
GrantCommon Stock | 410,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039335 · doc4.xml · nonDerivative · entry 2 Edick Paul R · CIK 0001531178 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,064 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:49 UTC |
Edick Paul RDirector · See Remarks
|
GrantCommon Stock | 197,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039335 · doc4.xml · nonDerivative · entry 1 Edick Paul R · CIK 0001531178 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,231 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective time, net of shares withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective time, net of shares withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 8 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-18 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 7 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 34,977 | Not disclosed Strike: $12.50 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 6 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,977 Underlying: Common Stock · 34,977 shares Expires 2028-05-15 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F7 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 28,072 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 5 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,072 Underlying: Common Stock · 28,072 shares Expires 2028-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F7 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 25,136 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 4 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,136 Underlying: Common Stock · 25,136 shares Expires 2027-06-11 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 160,335 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · derivative · entry 3 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,335 Underlying: Common Stock · 160,335 shares Expires 2027-02-03 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantCommon Stock | 193,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · nonDerivative · entry 2 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,829 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:47 UTC |
Shannon John Patrick JrSee Remarks
|
GrantCommon Stock | 70,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039333 · doc4.xml · nonDerivative · entry 1 Shannon John Patrick Jr · CIK 0001553595 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,496 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · derivative · entry 7 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-08-14 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F9 · derivative.exercise_date: 50% of these options vested on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 32,500 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · derivative · entry 6 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F8 · derivative.exercise_date: 25% of these options vested on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 3,826 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · derivative · entry 5 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,826 Underlying: Common Stock · 3,826 shares Expires 2028-10-04 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7 · derivative.exercise_date: 25% of the options vested on October 5, 2019, with the remaining 75% of the shares vesting in 36 equal monthly installments on the fifth day of each month thereafter. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 65,295 | Not disclosed Strike: $12.50 | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · derivative · entry 4 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,295 Underlying: Common Stock · 65,295 shares Expires 2028-05-14 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of the options vested on May 15, 2019, with the remaining 75% of the shares vesting in 36 equal monthly installments on the fifteenth day of each month thereafter. F10 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 30,879 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · derivative · entry 3 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,879 Underlying: Common Stock · 30,879 shares Expires 2028-01-30 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: 25% of the options vested on January 16, 2019, with the remaining 75% of the shares vesting in 36 equal monthly installments on the sixteenth day of each month thereafter. F10 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantCommon Stock | 180,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · nonDerivative · entry 2 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,366 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 23:37 UTC |
Hecht BethSee Remarks
|
GrantCommon Stock | 26,366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039317 · doc4.xml · nonDerivative · entry 1 Hecht Beth · CIK 0001652410 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,366 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 8 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-14 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7 · derivative.exercise_date: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 32,500 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 7 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2029-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 21,401 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 6 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,401 Underlying: Common Stock · 21,401 shares Expires 2028-10-04 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 39,633 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 5 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,633 Underlying: Common Stock · 39,633 shares Expires 2028-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 5,280 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 4 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,280 Underlying: Common Stock · 5,280 shares Expires 2027-06-12 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 33,686 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · derivative · entry 3 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,686 Underlying: Common Stock · 33,686 shares Expires 2027-02-04 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantCommon Stock | 78,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · nonDerivative · entry 2 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,583 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:38 UTC |
JOHNSON KENNETH ERLANDSee Remarks
|
GrantCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039319 · doc4.xml · nonDerivative · entry 1 JOHNSON KENNETH ERLAND · CIK 0001743774 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · derivative · entry 8 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-08-14 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F7 · derivative.exercise_date: 50% of these options shall vest on the first anniversary of the vesting commencement date, 25% shall vest on the 18-month anniversary of the vesting commencement date and the remaining 25% shall vest on the second anniversary of the vesting commencement date. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $13.88 | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · derivative · entry 7 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 14,036 | Not disclosed Strike: $5.93 | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · derivative · entry 6 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,036 Underlying: Common Stock · 14,036 shares Expires 2028-01-31 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F6 · derivative.exercise_date: 25% of these options shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. F8 · derivative.exercise_date: These options are early exercisable. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,266 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · derivative · entry 5 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,266 Underlying: Common Stock · 11,266 shares Expires 2027-06-12 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 28,072 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · derivative · entry 4 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,072 Underlying: Common Stock · 28,072 shares Expires 2027-02-04 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 11,228 | Not disclosed Strike: $0.69 | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · derivative · entry 3 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,228 Underlying: Common Stock · 11,228 shares Expires 2022-02-23 F4 · kind: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4 · price: At the Merger Effective Time, each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F5 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantCommon Stock | 110,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · nonDerivative · entry 2 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,780 F3 · security: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · kind: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. F3 · price: Represents restricted stock units each representing a contingent right to receive one share of HoldCo common stock (the "HoldCo RSU"). At the Merger Effective Time, each restricted stock unit representing a contingent right to acquire one share of Xeris common stock (the "Xeris RSU") that was outstanding immediately prior to the Merger Effective Time was automatically converted into a HoldCo RSU on the same terms and conditions (including any applicable vesting and settlement terms) as were applicable to such Xeris RSU immediately prior to the Merger Effective Time, including that the number of shares of HoldCo common stock subject to such HoldCo RSU is equal to the number of shares that were subject to the Xeris RSU. Read SEC document |
| October 05, 2021 Filed Oct 5, 2021 19:46 UTC |
PRESTRELSKI STEVENChief Scientific Officer
|
GrantCommon Stock | 384,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039330 · doc4.xml · nonDerivative · entry 1 PRESTRELSKI STEVEN · CIK 0001744027 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,780 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · kind: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2 · price: (Continued from Footnote 1) At the effective time of the Merger (the "Merger Effective Time"), all existing shares of Xeris common stock (the "Xeris common stock") were cancelled and automatically converted into the right to receive HoldCo common stock on a one-for-one basis. This amount includes shares of HoldCo common stock received upon vesting of Xeris restricted stock units that were vested as of the Merger Effective Time, net of shares withheld for tax. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,650 | $2.37 Strike: $2.37 | $46,570.50 |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 7 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,650 Underlying: Common Stock · 19,650 shares Expires 2031-10-05 F4 · derivative.exercise_date: One third of these options shall vest in equal annual installments until the third anniversary of the date of grant. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,360 | Not disclosed Strike: $9.89 | Not disclosed |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 6 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2028-05-15 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,360 | Not disclosed Strike: $5.62 | Not disclosed |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 5 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2027-05-11 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,360 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 4 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2026-05-12 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantStock Option (Right to Buy) · Derivative | 7,357 | Not disclosed Strike: $22.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 3 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 Underlying: Common Stock · 7,357 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,600 | Not disclosed Strike: $22.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,600 Underlying: Common Stock · 19,600 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:30 UTC Amendment |
Kong GarhengDirector
|
GrantCommon Stock | 50,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039750 · doc4a.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,170 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 19,650 | $2.37 Strike: $2.37 | $46,570.50 |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 8 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,650 Underlying: Common Stock · 19,650 shares Expires 2031-10-05 F4 · derivative.exercise_date: One third of these options shall vest in equal annual installments until the third anniversary of the date of grant. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 68,600 | Not disclosed Strike: $2.43 | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 7 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,600 Underlying: Common Stock · 68,600 shares Expires 2030-04-08 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 215,600 | Not disclosed Strike: $1.99 | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 6 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,600 Underlying: Common Stock · 215,600 shares Expires 2029-11-14 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,360 | Not disclosed Strike: $9.89 | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 5 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2028-05-15 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,360 | Not disclosed Strike: $5.62 | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 4 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2027-05-11 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 31,360 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 3 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,360 Underlying: Common Stock · 31,360 shares Expires 2026-05-12 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,367 | Not disclosed Strike: $22.39 | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 Underlying: Common Stock · 10,367 shares Expires 2025-10-16 F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time. F3 · derivative.exercise_date: These options are fully vested as of the date hereof. Read SEC document |
| October 05, 2021 Filed Oct 8, 2021 22:29 UTC Amendment |
JOHNSON JOHNDirector
|
GrantCommon Stock | 478,312 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039749 · doc4a.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,312 F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.